According to the researchers of this new study, the biomarker may have potential for use with clinical scores in treatment decisions or in clinical trials that focus on hidradenitis suppurativa (HS).
New research is signaling that a simple and cost-effective biomarker may be used to monitor the severity of hidradenitis suppurativa (HS).
The retrospective study of patients with the condition showed that pan-immune-inflammation value (PIV), across a variety of biomarkers, had the strongest indications for HS severity. According to the researchers, whose findings appear in Journal of the European Academy of Dermatology and Venereology, the biomarker may be able to be used with clinical scores in treatment decisions or in clinical trials.
“In routine clinic evaluation of HS disease, severity based only on clinical features can be a challenge (eg, distinguishing Hurley II and Hurley III),” explained the researchers. “Hence, diagnostic and monitoring biomarkers for HS are needed. Data regarding the association of serum markers of inflammation with HS disease severity have recently been reported by our research group.”
Across the 142 patients with HS and 35 sex- and age-matched controls, the researchers saw a significant positive correlation between modified HS score (mHSS) and PIV (r = 0.32; P < .0001), in addition to neutrophil to lymphocyte ratio (NLR) (r = 0.17; P = .0415), monocyte to lymphocyte ratio (MLR) (r = 0.23; P = .0052), and systemic immune-inflammation index (SII) (r = 0.19; P = 0.0222). They also found that the platelet to neutrophil ratio (PNR) had a negative correlation with mHSS (r = –0.21; P = .0124).
Compared with the controls, patients with HS had significantly higher PIV and SII, although PIV—a combination of neutrophil, platelet, and monocyte counts—was the only biomarker significantly associated with severity based on the Youden index, with an index of 0.56.
PIV also showed an area under the curve (AUC) of 0.79 (95% CI, 0.71-0.85; P < .0001), with a sensitivity of 59.3 and a specificity of 96.5.
The platelet to lymphocyte ratio (PLR), MLR, and PNR were all significantly lower in these patients compared with the controls. Previous research has connected NLR and PLR with the severity of skin inflammatory diseases, although this correlation has not previously been studied in HS specifically.
“On the basis of our data, PLR does not appear to be a suitable biomarker for disease activity or severity,” described the researchers. “By contrast, NLR, MLR, PNR, SII, and PIV positively or negatively correlated with HS severity. However, the AUC values for Hurley stage and [Severity Assessment of Hidradenitis Suppurativa score] were relatively poor for NLR, MLR, PNR, and SII.”
Reference
Gambichler T, Hessam S, Cramer P, Rached NA, Bechara G. Complete blood collection-based systemic inflammation biomarkers for patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. Published online April 24, 2022. doi:10.1111/jdv.18175
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More